Request Demo

Last update 09 Oct 2025

Modafinil

Last update 09 Oct 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryModafinil, a minuscule molecular compound marketed as PROVIGIL, received its initial approval in 1992. This drug is principally utilized to enhance vigilance among adult patients who are plagued by excessive sleepiness, a symptom of narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). However, it is important to note that PROVIGIL is not intended to treat the underlying causes of these sleep disorders; rather, its function is to heighten the patient's aptitude to remain alert during daylight hours. As a central nervous system stimulant, Modafinil operates by augmenting the activity of particular chemicals located within the brain that are implicated in regulating the sleep-wake cycle.

Drug Type

Small molecule drug

Synonyms

2-((diphenylmethyl)sulfinyl)acetamide, Alertec, Attenace

+ [25]

Target

DAT

Action

antagonists

Mechanism

DAT antagonists(Dopamine transporter antagonists)

Therapeutic Areas

Nervous System DiseasesRespiratory DiseasesOther Diseases

Active Indication

Idiopathic HypersomniaDisorders of Excessive SomnolenceNarcolepsy+ [3]

Inactive Indication

Alzheimer DiseaseApathyAttention Deficit Disorder With Hyperactivity+ [10]

Originator Organization

Teva Pharmaceuticals Europe BV

Active Organization

Mitsubishi Tanabe Pharma Corp.

Xiangbei Welman Pharmaceutical Co., Ltd.

Teva Pharmaceutical Industries Ltd.

+ [3]

Inactive Organization

Cephalon, Inc.

License Organization

Neuraxpharm

Drug Highest PhaseApproved

First Approval Date

United States (24 Dec 1998),

NarcolepsySleep Apnea, ObstructiveSleep Disorders, Circadian Rhythm+ [1]

RegulationOrphan Drug (United States), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC15H15NO2S

InChIKeyYFGHCGITMMYXAQ-UHFFFAOYSA-N

CAS Registry68693-11-8

213

Clinical Trials associated with Modafinil

NCT06354985

/ Not yet recruitingPhase 3IIT

Modafinil and Exercise for Post Stroke Fatigue (MODEX)

A stroke happens when blood flow to the brain is stopped and the brain gets damaged. At least half of people with a stroke have fatigue months and even years later. A lot of people report fatigue as one of the worst symptoms post stroke that can affect daily activities and the length and quality of life. Though all the reasons for fatigue after stroke and how to best treat it are not fully understood, the investigators think that fatigue results from the stroke changing the brain, reducing physical fitness, and decreasing muscle strength. A stroke can also affect sleep and mood, which can impact how people feel too. It is also not known why women experience more fatigue than men after a stroke.
Some studies have tested a drug called Modafinil for post stroke fatigue, while other studies have tested exercise for it. Yet, there is unclear evidence for either treatment, so this study has the following aim:
1. Test if Exercise plus Modafinil is better than Exercise plus a Sugar Pill
This study will take place at up to 6 Canadian research sites to give a good representation of people after a stroke. Each person will be tested on fatigue, mood, fitness, thinking skills, sleep, and usual activity levels.
Participants will be assigned at random (like flipping a coin) to 1 of 2 groups:
1. Sugar Pill plus Exercise
2. Modafinil plus Exercise
The treatment will last 8 weeks. The Modafinil or Sugar Pill will be taken once a day. The exercise will be delivered virtually by a trained therapist over computer to people at home 3 times a week. Change in fatigue, quality of life, and other outcomes will be measured over 6 months.
The investigators will assess the results to identify the best treatment for post stroke fatigue and hope to be able to find a treatment that will help reduce fatigue and improve quality of life after a stroke.

Start Date01 Sep 2025

Sponsor / Collaborator

University Health Network

NCT05333250

/ Not yet recruitingPhase 3IIT

Modafinil to Improve Fatiguability (MODIFY): Modafinil vs. Placebo Vanguard RCT

Cancer-related fatigue (CRF) and cancer-related cognitive impairment (CRCI) are among the most commonly reported disabling symptoms experienced by patients with advanced cancer. However, there are currently limited evidence-based pharmacologic interventions available. The investigators will conduct a Vanguard Randomized Clinical Trial (RCT) to estimate the effect of modafinil in managing CRF and CRCI, and to test the feasibility of carrying out the study.

Start Date01 Jan 2025

Sponsor / Collaborator

Ottawa Hospital Research Institute

[+2]

NCT06592352

/ RecruitingPhase 2IIT

MODAFIMS: An Open-label, Single-center Clinical Trial to Evaluate Predictors of Response to MODAFinil in the Treatment of Cognitive Deficits in Patients With Multiple Sclerosis

This is a phase II/exploratory clinical trial with a single-center, open-label design to evaluate the effect of modafinil on cognitive deficits in adult patients with multiple sclerosis and identify predictors of response using functional Magnetic Resonance Imaging (fMRI).

Start Date27 Aug 2024

Sponsor / Collaborator

The Clinical Academic Center of Braga

100 Clinical Results associated with Modafinil

100 Translational Medicine associated with Modafinil

100 Patents (Medical) associated with Modafinil

2,303

Literatures (Medical) associated with Modafinil

01 Nov 2025·INTERNATIONAL JOURNAL OF PHARMACEUTICS

Controlled API crystallization during additive manufacturing of solid dosage form for flexible integrated pharmaceutical manufacturing

Article

Author: Duconge, Jorge ; Romañach, Rodolfo J ; Cersonsky, Rose K ; Stelzer, Torsten ; Mbodji, Aliou ; Cruz, Kelitsha Mulero ; Coquerel, Gérard ; Gómez, Andrea Arroyo ; Vlaar, Cornelis P ; Monbaliu, Jean-Christophe M ; Yu, Lian ; Zhang, Geoff Gz

Conventional manufacturing of solid dosage forms (e.g., tablets, capsules) demands multiple unit operations and handling of solids, known to be more challenging than handling liquids. To circumvent these challenges, this study explored liquid dispensing to manufacture an oral solid dosage form. The presented additive manufacturing process dispenses a solution (drug substance, solvent, polymer) into a carrier (capsule). Upon controlled solvent evaporation, the model active pharmaceutical ingredient, racemic modafinil (MOD), crystallizes inside a polymer matrix (polyethylene glycol) generating a crystalline solid dispersion. The critical process parameters (e.g., temperature, concentration, evaporation rate, choice of solvent) and key performance metrics were evaluated to ensure robust crystalline solid dispersion manufacturing. The coupled crystallization and formulation process delivers the desired polymorph form I of MOD inside a crystalline solid dispersion that matches the quality attributes of commercially formulated MOD tablets (Provigil®) following US Pharmacopeia methods. Moreover, the developed workflow and insights presented provide a generalizable approach applicable to other drug substance - polymer - solvent systems, independent if crystalline or amorphous solid dispersion is needed. Ultimately, this study demonstrates the flexible (additive) formulation of solid dosage forms, needed for, e.g., point-of-use manufacturing in remote areas or personalized medicine via a process intensification approach.

01 Nov 2025·CURRENT OPINION IN PULMONARY MEDICINE

Understanding idiopathic hypersomnia: diagnosis, pathophysiology, and management

Review

Author: Shahzadi, Madeeha ; Thorpy, Michael J ; Monderer, Renee

Purpose of review:

Idiopathic hypersomnia is a chronic and often disabling sleep disorder characterized by excessive daytime sleepiness despite adequate or prolonged nighttime sleep. With recent advances in diagnosis and treatment, this review is timely in addressing evolving approaches to understanding and managing idiopathic hypersomnia, a condition that remains underrecognized and frequently misdiagnosed.

Recent findings:

Idiopathic hypersomnia is clinically distinct from narcolepsy, lacking REM-related features such as cataplexy and hypnagogic hallucinations. Until recently, treatment options for idiopathic hypersomnia were limited and often off-label. The 2021 FDA approval of low-sodium oxybate (LXB) marked the first medication specifically indicated for idiopathic hypersomnia. Additional agents such as modafinil, pitolisant, and traditional stimulants are used off-label with varying efficacy. Ongoing research is exploring promising treatments, including orexin-2 receptor agonists (e.g. ALKS 2680, ORX-750), serdexmethylphenidate, and flumazenil, which offer new hope for personalized management.

Summary:

Growing insights into the pathophysiology and clinical features of idiopathic hypersomnia have led to improved diagnostic clarity and therapeutic innovation. These developments carry significant implications for clinical practice, offering hope for better symptom control and quality of life in affected individuals. Ongoing research is crucial for refining treatment strategies and deepening our understanding of this complex condition.

01 Oct 2025·DRUG AND ALCOHOL DEPENDENCE

Cocaine craving and use during pharmacotherapy trials for cocaine use disorder: A multi-trajectory analysis

Article

Author: Leggio, Lorenzo ; Nguyen, Trang Quynh ; Aminesmaeili, Masoumeh ; Farokhnia, Mehdi ; Mojtabai, Ramin ; Dunn, Kelly E ; Bergeria, Cecilia ; Susukida, Ryoko

BACKGROUND:

There is limited research on the course of drug craving in treatment trials of stimulant use disorders. This study examined trajectories of cocaine craving and use and their associations with other outcomes of cocaine use disorder in pharmacotherapy trials of cocaine use disorder.

METHODS:

In 1070 participants from 6 randomized controlled trials testing selegiline, baclofen, cabergoline, modafinil, reserpine, and tiagabine, we used multi-trajectory modeling to identify joint trajectories of weekly-measured cocaine craving and use. Association of these trajectories with Addiction Severity Index (ASI) health and social outcomes was assessed.

RESULTS:

A 3-trajectory model with High craving/High use (40.0 %), Decreasing craving/High use (36.8 %), and Decreasing craving/Decreasing use (23.2 %) groups was the most parsimonious. Compared to the High craving/High use group, the Decreasing craving/Decreasing use group experienced significantly greater improvement on ASI domains of drug use (change score = -13.7 vs. -3.3), alcohol use (-7.3 vs. -4.4), psychiatric status (-5.6 vs. 0.7) and relationships status (-7.0 vs. -2.8) (all p < 0.05). Compared to placebo, those on modafinil 200mg/day were more likely to be in the Decreasing craving/Decreasing use group (Relative Risk Ratio [RRR]=4.84, 95 % CI=1.38-17.00) or Decreasing craving/High use group (RRR=5.55, 2.04-14.08) than in the High craving/High use group.

CONCLUSIONS:

Trajectories of craving/drug use in clinical trials for cocaine use disorder are heterogeneous. Participants experiencing the greatest reduction in cocaine craving/use experienced the greatest improvement in other measures of drug use and psychosocial functioning, supporting the utility of reduced craving/use as a clinically relevant outcome in pharmacotherapy trials of people with cocaine use disorder.

News (Medical) associated with Modafinil

08 Sep 2025

·www.prnewswire.com

Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025

E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1 TOKYO, Sept. 8, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the results from a Phase Ib clinical trial (NCT06462404) of its in-house developed novel selective orexin 2 receptor agonist E2086 have been presented at the World Sleep 2025 congress, held in Singapore from September 5 to 10. These data demonstrate that once-daily dosing of E2086 has the potential to improve daytime wakefulness in individuals with narcolepsy type 1 (NT1). Continue Reading Clinical Trial Design This randomized, double-blind, single-dose, multiple crossover, Phase Ib clinical trial was conducted in the United States and Canada to evaluate the efficacy, safety, and tolerability of E2086 in people meeting criteria for NT1, compared with placebo and an existing treatment (modafinil). There were a total of 21 patients in the clinical trial (21 patients received the study medication, 19 patients completed the trial). Participants received a single dose of one of five treatments (E2086 5 mg, 10 mg, 25 mg, placebo, or modafinil) shortly after waking, efficacy assessments were conducted for each treatment. Efficacy was assessed using the objective Maintenance of Wakefulness Test (MWT)*1 to evaluate excessive daytime sleepiness (EDS), and subjective sleepiness was measured using the Karolinska Sleepiness Scale (KSS)*2 at the end of each MWT session. Clinical Trial Results As evaluated by MWT, all doses of E2086 demonstrated statistically significant longer sleep latencies*3 – a measure of the ability to stay awake – compared with placebo (P<0.0001 for all doses) and modafinil (E2086 5 mg: P=0.0009; E2086 10 mg and 25 mg: P<0.0001) (See the figure below). For the KSS, all doses of E2086 showed statistically significant higher alertness compared with placebo (P<0.0001), while E2086 10 mg and 25 mg demonstrated statistically significantly higher alertness compared with modafinil (P<0.0001). These outcomes confirmed the Proof of Mechanism for E2086. Treatment-emergent adverse events (TEAEs), based on the 21 patients who received the study medication in the clinical trial, exhibited a dose-dependent trend. The four most frequently observed TEAEs with E2086 included increased urinary frequency (E2086 5 mg: 14.3%, 10 mg: 23.8%, 25 mg: 52.4%), nausea (14.3%, 19.0%, 47.6%), dizziness (4.8%, 23.8%, 38.1%), and urinary urgency (9.5%, 19.0%, 38.1%). No participants discontinued due to TEAEs, and most TEAEs were mild to moderate in severity. No serious TEAEs were reported. Katsutoshi Ido, Ph.D., Chief Scientific Officer at Eisai, commented: "At World Sleep 2025, we presented data supporting the potential of E2086 to improve daytime wakefulness in people diagnosed with narcolepsy type 1. Narcolepsy is a condition with high unmet medical needs, characterized not only by excessive daytime sleepiness but also by symptoms such as cataplexy, hypnagogic/hynopompic hallucinations, and sleep paralysis, all of which significantly impair the quality of life of those affected. The efficacy and safety findings from this trial warrant further investigation in the narcolepsy patient population." Orexin is a neurotransmitter that plays a central role in regulating sleep and wakefulness. Inhibiting orexinergic neurons is believed to promote a natural transition from wakefulness to sleep. Conversely, activating orexinergic neurons is believed to help maintain a more stable state of wakefulness. From the perspective of inhibiting orexinergic neuron activity, Eisai has developed the insomnia treatment DAYVIGO ® (generic name: lemborexant) an orexin receptor antagonist that is available in more than 25 countries worldwide. Furthermore, leveraging the orexin platform established through the development of DAYVIGO, Eisai has created E2086, an orexin receptor agonist that activates orexinergic neurons. In addition to DAYVIGO, Eisai aims to contribute to people living with sleep disorders through the development of E2086. *1 Maintenance of Wakefulness Test (MWT): An objective test that evaluates the ability to stay awake in a sleep-conducive environment. The test is conducted in a quiet examination room with the lights turned off, consisting of four 40-minute sessions carried out at two-hour intervals throughout the day, during which the time taken to fall asleep (sleep latency) is measured using electroencephalography. *2 Karolinska Sleepiness Scale (KSS): A simple subjective scale used to assess the current intensity of sleepiness on a 9-point scale, ranging from "1 - Very clearly awake" to "9 - Very sleepy, struggling against sleepiness". *3 Sleep latency: The amount of time it takes to fall asleep. MEDIA CONTACTS: Eisai Co., Ltd. Public Relations Department, TEL: +81-(0)3-3817-5120 Eisai Europe, Ltd. EMEA Communications Department + 44 (0) 797 487 9419 Eisai Inc. (U.S.) Libby Holman + 1-201-753-1945 [Notes to editors] 1. About E2086 E2086 is Eisai's in house discovered novel selective orexin 2 receptor agonist. Nonclinical studies have demonstrated statistically significant increases in time spent awake and significant reductions in rates of cataplexy. Individuals with a deficiency of orexin demonstrate excessive daytime sleepiness (EDS), as exemplified by patients with narcolepsy Type 1, demonstrate a loss of orexinergic neurons, and low cerebrospinal fluid (CSF) orexin levels. E2086 has the potential to improve patients' symptoms by enhancing orexin receptor activity. 2. About narcolepsy Narcolepsy is a chronic sleep disorder that is characterized by EDS. Narcolepsy is classified into two subtypes, type 1 (narcolepsy with cataplexy) and type 2 (narcolepsy without cataplexy). Due to problems with fatigue, cognition, and persistence of residual symptoms despite treatment, disease burden for narcolepsy is high.1 References 1. Maski. K, et.al. Listening to the Patient Voice in Narcolepsy: Diagnostic Delay, Disease Burden, and Treatment Efficacy. J. Clinical Sleep Medicine. 2017, 13 (3) p419-, SOURCE Eisai Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 1

08 Sep 2025

·www.biopharmadive.com

A new class of sleep drugs draws Wall Street’s attention

Drug developers from around the world rang in a new era of sleep medicine Monday, as data from a series of clinical trials show narcolepsy can be effectively treated by amplifying a specific brain protein.That protein, called orexin-2, helps regulate important body functions like appetite, arousal and wakefulness, which has in turn made it a promising target for drug companies. Johnson & Johnson, for instance, hopes that by blocking orexin-2, its experimental medicine seltorexant can be used to combat insomnia in patients with major depression.More commonly, though, developers are looking to boost this protein to keep people with narcolepsy awake longer. The furthest along in this pursuit is Takeda Pharmaceutical with its drug oveporexton, which recently met the main and secondary goals of two late-stage clinical trials that focused on the most common, Type 1 form of narcolepsy.On Monday, at a medical conference focused on sleep therapies, Takeda presented more detailed results from these studies. In each, researchers evaluated whether oveporexton was any better than a placebo at keeping participants awake by using what Sarah Sheikh, Takedas head of global development, describes as the most boring test of all time.This Maintenance of Wakefulness Test places participants in a dark, quiet, peaceful room and measures how long it takes them to fall asleep. The exam has several rounds, with each lasting roughly 40 minutes. According to Takeda, at the start of its studies, most participants were asleep within five minutes. But 12 weeks in, those who were taking 2 mg doses of oveporexton twice daily were staying awake about 20 minutes to 25 minutes a clinically meaningful improvement.One hallmark of Type 1 narcolepsy is a loss of muscle control known as cataplexy. Takeda additionally said the median weekly rates of cataplexy decreased more than 80% for oveporexton-treated patients during its studies. The median number of days per week that patients experienced no cataplexy had also grown, from 0 to between 4 and 5.This is the first time any drug in this field has ever shown this magnitude of effect, Sheikh said in an interview ahead of the presentation.Takeda highlighted other findings as well, like that drug-treated patients reported significant improvements in their quality of life. Oveporexton was generally well tolerated, too, as researchers did not observe serious adverse events related to treatment. There were no liver toxicity issues, nor were there any signs of patients experiencing visual disturbances a potential safety concern with orexin drugs that analysts have homed in on.The most common adverse events, Takeda said, were insomnia and frequent urination, and a majority were transient.With these results in hand, the company plans to submit its drug for approval by the end of March. Jefferies analyst Stephen Barker wrote in a note to clients how the fresh data make his team increasingly confident oveporexton will dominate a market that Takeda estimates having as many as 120,000 patients in the U.S. alone.Takeda is currently well ahead of its closest competitor, and its drug, if ultimately approved, could achieve annual sales of $1 billion, according to Barker.While Takeda may have the lead, companies like Alkermes, Eisai and Centessa Pharmaceuticals are working to make up ground.At the medical conference, Alkermes gave a more in-depth look into a mid-stage study where three different doses of its once-daily drug alixorexton each beat a placebo on that Maintenance of Wakefulness Test. After six weeks, the drug-treated groups were able to stay awake for 24 to 28 minutes and were showing meaningful improvements on sleepiness and cataplexy, Alkermes said. And, as with Takedas studies, most treatment-emergent adverse events were mild or moderate.The most common adverse events were frequent or abnormal urination, insomia, excessive saliva secretion and blurred vision, though Alkermes noted how there were no clinically meaningful changes in vital signs, eye exams, or liver or kidney function.Overall, the data was good and about as expected, wrote Marc Goodman, an analyst at Leerink Partners. Goodman added that the once-daily and flexible dosing of alixorexton should be an advantage for Alkermes, as the #2 player.Eisai also presented data from an early-stage study with 21 participants, who either received a placebo, an existing medication known as modafinil, or one of three doses of the companys drug E2086. Eisai said all doses appeared to keep patients awake significantly longer in that wakefulness test. The most common treatment-emergent adverse events were dizziness, nausea, and frequent or urgent urination. None were classified as serious.Katsutoshi Ido, Eisais chief scientific officer, said in a satement the results warrant further investigation of E2086 as a potential treatment for narcolepsy.Takedas stock price had slipped 1% in U.S. trading by Monday afternoon. Eisai shares, meanwhile, rose nearly 4% on the Tokyo stock exchange, while Alkermes were down more than 6% on the Nasdaq.The Food and Drug Administration has approved a few orexin-blocking agents for insomnia. They include Merck & Co.s Belsomra, Idorsias Quviviq and Eisais Dayvigo. '

Clinical Result

07 Jan 2025

·www.prnewswire.com

Neuraxpharm to further grow branded business with the acquisition of two leading narcolepsy treatments, Provigil® and Nuvigil®

Provigil® (modafinil) and Nuvigil® (armodafinil), two of the most trusted and widely prescribed brands in the narcolepsy category, will increase Neuraxpharm's global CNS presence and support market entry into new territories including Australia BARCELONA, Spain and DÜSSELDORF, Germany, Jan. 7, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end of December 2024 Provigil® (modafinil) and Nuvigil® (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets outside the US^. Provigil's main market is Europe, with significant sales in France, Spain and Italy. Nuvigil is present in international markets with significant sales in Australia and Mexico. Both Provigil and Nuvigil are orally administered CNS stimulants indicated to improve wakefulness and reduce Excessive Daytime Sleepiness (EDS) in adult patients with narcolepsy, both with and without cataplexy. This acquisition is in line with Neuraxpharm's strategy to grow strong CNS brands and bring them to increasing numbers of patients worldwide. It will enable entry into new territories such as Australia, where Neuraxpharm also plans to launch first-in-class multiple sclerosis treatment ublituximab (BRIUMVI®), and will furthermore reinforce Neuraxpharm's presence in Mexico, where the Company established an office in 2023. The transaction follows the acquisition from Sanofi of two established product portfolios in 2023 and the securing of a landmark partnership with TG Therapeutics also in 2023 to commercialise ublituximab outside the US*. In 2020, Neuraxpharm acquired market-leading child epilepsy treatment Buccolam® (oromucosal midazolam) from Takeda, and in September last year Neuraxpharm received a positive CHMP opinion from the European Medicine Agency to extend Buccolam's indication to include the treatment of epilepsy in adults. Dr. Jörg-Thomas Dierks, CEO of Neuraxpharm, commented: "Today's acquisition is an example of how Neuraxpharm can harness its neurology-focused approach, broad international platform and entrepreneurial capabilities to expand strong CNS brands. These two leading narcolepsy treatments will be added to our broad and growing CNS portfolio. We will leverage our specialisation and reach to grow these products in existing and new markets, thereby bringing market-leading treatments to more CNS patients with unmet needs around the world." No financial details of the transaction have been disclosed. ^ Republic of Korea, Japan, Thailand and the United States are not included in this acquisition. * Territories outside the United States, Canada, Mexico, and excluding certain Asian countries previously partnered. About the Neuraxpharm Group Neuraxpharm is a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS), including both psychiatric and neurological disorders. It has a unique understanding of the CNS market built over 35 years. Neuraxpharm is constantly innovating, with new products and solutions to address unmet patient needs and is expanding its portfolio through its pipeline, partnerships, and acquisitions. The company has c.1,000 employees and develops and commercializes CNS products through a direct presence in more than 20 countries in Europe, two in Latin America, one in the Middle East, and globally via partners in more than 50 countries. Neuraxpharm is backed by funds advised by Permira. Neuraxpharm manufactures many of its pharmaceutical products at Neuraxpharm Pharmaceuticals (formerly Laboratorios Lesvi) in Spain. For more information, please visit SOURCE Neuraxpharm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug ApprovalAcquisitionClinical Result

100 Deals associated with Modafinil

External Link

KEGG	Wiki	ATC	Drug Bank
D01832	Modafinil	N06BA07	DB00745

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Idiopathic Hypersomnia	Japan	Alfresa Pharma Corp.	21 Feb 2020
Disorders of Excessive Somnolence	Canada	Teva Pharmaceutical Industries Ltd.	24 Mar 1999
Narcolepsy	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998
Sleep Apnea, Obstructive	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998
Sleep Disorders, Circadian Rhythm	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998
Sleepiness	United States	Nuvo Pharmaceuticals (Ireland) DAC	24 Dec 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alzheimer Disease	Phase 3	United States	Cephalon, Inc.	01 Jul 2005
Apathy	Phase 3	United States	Cephalon, Inc.	01 Jul 2005
Cataplexy	Phase 3	United States	Cephalon, Inc.	01 Oct 2004
Cataplexy	Phase 3	Canada	Cephalon, Inc.	01 Oct 2004
Obstructive Sleep Apnea Hypopnea Syndrome	Phase 3	United States	Cephalon, Inc.	01 Oct 2004
Obstructive Sleep Apnea Hypopnea Syndrome	Phase 3	Canada	Cephalon, Inc.	01 Oct 2004
Attention Deficit Disorder With Hyperactivity	Phase 3	United States	Cephalon, Inc.	01 Sep 2003
Depressive Disorder	Phase 2	Germany	Cephalon, Inc.	01 May 2008
Sleep Deprivation	Phase 2	Germany	Cephalon, Inc.	01 May 2008
Fatigue	Phase 2	United States	Cephalon, Inc.	01 May 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03772314 (Pubmed \| CNS Drugs) Manual	Phase 2	Narcolepsy \| Idiopathic Hypersomnia	-	Modafinil	pkjlhlugqc(ycjuzjlxwc) = cgnbojfmvp wrauicvuhg (tuqwcrfyiv, 2.7) Not Met View more	Negative	21 Sep 2024
				Amphetamine-Dextroamphetamine	pkjlhlugqc(ycjuzjlxwc) = kjaafadohz wrauicvuhg (tuqwcrfyiv, 4.7) Not Met View more
NCT03621761 (COMBO-MS, ACTRIMS2023)	Phase 4	Multiple Sclerosis	336	Telephone-based Cognitive Behavioral Therapy (CBT)	kcbgkhkpwo(wdrszpmocd) = qsysmbpsbg idcaqrlfcr (dptscjwipv, 11.9)	Positive	30 May 2023
				Modafinil	kcbgkhkpwo(wdrszpmocd) = hgydezbedd idcaqrlfcr (dptscjwipv, 15.9)
NCT03621761 (COMBO-MS, CTgov)	Phase 4	Fatigue \| Multiple Sclerosis	343	Telephone-based Cognitive Behavioral Therapy (Cognitive Behavioral Therapy)	wsctfjkqvp(gincsusywh) = ywafjfzaqz ykiykloouk (wuknpkvcoy, 11.9) View more	-	27 Dec 2022
				Modafinil (Modafinil)	wsctfjkqvp(gincsusywh) = talqqmidto ykiykloouk (wuknpkvcoy, 15.9) View more
NCT03083132 (CTgov)	Phase 2	Mental Fatigue \| Parkinson Disease	21	modafinil 50mg (Early-start)	pzeeacrdon(kwvwqquwow) = fvirylxlgk obriohyeya (tbfzvrxops, 2.53) View more	-	27 Oct 2021
				Placebo oral capsule+modafinil 50mg (Delayed-start)	pzeeacrdon(kwvwqquwow) = pxsxhiufpt obriohyeya (tbfzvrxops, 1.62) View more
NCT01381718 (CTgov)	Phase 2	Cognition \| Neurotoxicity Syndromes \| Cognitive Dysfunction ... View more	112	Modafinil (Arm I - Modafinil)	ucszaixxrs(cnperkkril) = prvvvluotl mqqttszgdp (vazdmcyjvj, 0.71) View more	-	13 Aug 2021
				placebo (Arm II - Placebo)	ucszaixxrs(cnperkkril) = sieepkczax mqqttszgdp (vazdmcyjvj, 1.06) View more
NCT03185065 (TRIUMPHANT-MS, CTgov)	Phase 3	Fatigue \| Multiple Sclerosis	141	placebo (Placebo)	ejjezpuxwd(zrhvjsleru) = dprfqnjeps kodthdamgn (fetlrpmmzk, mxqtkvzwgq - asdycxsrqi) View more	-	19 Oct 2020
				Amantadine (Amantadine)	ejjezpuxwd(zrhvjsleru) = iyyabrmupe kodthdamgn (fetlrpmmzk, wsmfqjkmew - hitfaxhiiy) View more
NCT03424681 (CTgov)	Phase 2	Alcohol Use Disorder	12	Modafinil (Modafinil)	cbmxzfufru(gaddifzofc) = iaixyxmdbt zchkllscji (avtbmjhvvu, 27) View more	-	26 May 2020
				Placebo (Placebo)	cbmxzfufru(gaddifzofc) = tguwtxuxpa zchkllscji (avtbmjhvvu, 32) View more
NCT01913327 (APD, CTgov)	Phase 4	Schizoaffective disorder \| Schizophrenia	4	Aripiprazole+Modafinil (Aripiprazole)	vcrphxgbum(xohwmspxzz) = rxmmxjftcm bdhfvlxmly (qhfovmdhdc, depxesmmou - lurhofbdfz) View more	-	20 Apr 2020
				risperidone+Modafinil (Risperidone)	vcrphxgbum(xohwmspxzz) = hxdydmzwqm bdhfvlxmly (qhfovmdhdc, oreeecqqpr - pphhyhogxf) View more
WSC2019	Not Applicable	Sleep Apnea, Obstructive	1,714	Solriamfetol 150 mg	tpfnnvtkun(optqytxfoi) = rabtnhgbrh bmpejoqbjs (pdxvzooouk, 3% - 64%)	Positive	20 Sep 2019
NCT02494102 (ModOSA, CTgov)	Phase 4	Sleep Apnea, Obstructive \| Anesthesia \| Emergence Delirium	105	Placebo (Placebo)	zobxdhllap(jyiquwrtkz) = xjuoisinbv twvyicdzhd (fleunvdkcf, bnnctgthvz - ybspekdiae) View more	-	20 Jun 2019
				Modafinil (Intervention)	wwgfpngvty(wsqcgihtev) = cyswpjmmlv dqbixqffgb (odeiryeamv, notuzjucji - bdgwtwswcv) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis